The success of cancer gene therapies requiring in vivo gene transfer is severely hampered by the low efficacy of gene transfer, which has been difficult to improve. We therefore established a novel strategy to increase the share of transduced cells post gene transfer. We hypothesized that in vivo selection of tumor cells transduced with a suicide gene effectively enriches these cells within a tumor, thus allowing for an increased bystander effect after the prodrug is given, leading to enhanced eradication of tumor cells. We reasoned that in vivo enrichment should be achieved by exploiting the metabolism of the suicide gene product. For this 'enrichment-eradication' strategy we chose a fusion gene of cytosine deaminase and uracil phosphoribosyl transferase. Positive selection (enrichment) was to be achieved by concurrently giving N-(phosphonacetyl)-L-aspartate, an inhibitor of pyrimidine de novo synthesis, which leads to pyrimidine depletion-mediated death of non-transduced cells, and cytosine, to rescue fusion gene expressing cells via the pyrimidine salvage pathway. Negative selection (eradication) was to be induced by giving the prodrug 5-fluorocytosine. Indeed, murine NXS2 neuroblastoma cells transduced with the fusion gene were effectively enriched in vitro, leading to a near-complete bystander effect. In vivo enrichment-eradication of NXS2 cells led to decreased tumor growth. This proof-of-principle study shows that enrichment-eradication may compensate the effects of low in vivo gene transfer efficacy, a major obstacle in cancer gene therapy.
Introduction
The various approaches of gene therapy promise specific and efficient treatment of cancer. However, results of clinical trials have shown that, among other challenges, poor in vivo gene transfer efficiency poses a major obstacle for those approaches that rely on in vivo gene transfer into tumor cells. [1] [2] [3] [4] [5] [6] [7] [8] This applies to 'suicide gene' therapy, oncogene antagonism, antiangiogenesis gene therapy and some forms of immunotherapy. Thus, intense efforts are being directed at modifying vectors and delivery systems in order to improve gene transfer.
In addition, the killing effect of therapeutic genes on surrounding non-modified bystander cells, that is the 'bystander effect', 9 can be enhanced. This has been performed by increasing the number of gap junctions, which are necessary for export of the cytotoxic ganciclovir triphosphate from cells expressing herpes simplex virus thymidine kinase to bystander cells (reviewed by Mesnil and Yamasaki 10 ). Using suicide genes that do not depend on the export-limiting gap junctions for a bystander effect can also facilitate the bystander effect. The cytosine deaminase/5-fluorocytosine (CD/5-FC) system, for example, exerts a gap junction-independent bystander effect by outward diffusion of the cytotoxic metabolite 5-fluorouracil (5-FU) into the extracellular space. 11 Nevertheless, a strong bystander effect still requires a high percentage of cells expressing the suicide gene.
In this paper, we propose to compensate poor in vivo gene transfer into tumor cells by positive in vivo selection of tumor cells bearing the therapeutic gene. When a share of transfected cells sufficient for a complete bystander effect is reached, the killing mechanism is activated to eradicate the tumor. To make such an 'enrichmenteradication' strategy feasible and safe, we searched for a bifunctional suicide gene, which allows, in vivo, for initial positive selection as well as for terminal negative selection of the suicide gene-bearing tumor cells. The CD/5-FC system is a powerful eradication system, [12] [13] [14] especially when CD from yeast rather than from Escherichia coli is used, 15 and it has entered clinical trials. 16, 17 If appropriate culture conditions are provided, CD can also function as a positive selection system in vitro. 18, 19 When de novo pyrimidine synthesis is blocked by N-(phosphonacetyl)-Laspartate (PALA), CD-bearing cells are rescued from PALA-induced cell death if cytosine and also inosine are given to drive the pyrimidine salvage pathway. 18 This positive selection hinges on the addition of inosine to metabolize sufficient uridine necessary for rescue. CD/5-FC with PALA constitutes a promising bifunctional suicide gene, however, this system has not been applied in vivo, most likely because of the complexity of simultaneously adjusting appropriate levels of PALA, cytosine and inosine in vivo.
We show in this proof-of-principle paper that, after ex vivo gene transfer, a fusion gene of yeast CD and uracil phosphoribosyl-transferase in the presence of PALA and cytosine enriches the suicide gene-bearing tumor cells in vitro and in vivo (the system is depicted in Figure 1 ). Enrichment strongly enhanced the number of CDexpressing cells, thus increasing the degree of the bystander effect in the subsequent eradication step when the prodrug 5-FC was given. This led to superior tumor growth inhibition compared to conventional suicide gene therapy without prior enrichment.
Thus, in principle, the enrichment-eradication principle may increase the efficacy of cancer gene therapy by compensating the limitations caused by low in vivo gene transfer into tumor cells.
Materials and methods

Chemicals
PALA was provided by the Drug Synthesis & Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, MD. 5-FC, cytosine and methylthiazoletetrazolium (MTT) salt were from Sigma-Aldrich, Munich, Germany. The gcyclodextrin derivative was obtained from Wacker Chemie, Burghausen, Germany.
Cell culture
The murine neuroblastoma cell line NXS2 was obtained from R Reisfeld at the Scripps Institute, La Jolla, CA and grown in Dulbecco's Modified Eagle Medium (DMEM; GibcoBRL, Life Technologies, Eggenstein, Germany) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and penicillin/streptomycin (all from GibcoBRL). Two ml of medium per well was used for six-well-plates and 0.2 ml per well for 96-well-plates. Cells were maintained at 37.01C and 5% CO 2 in a humidified atmosphere.
Plasmid construction
The CD/uracil phosphoribosyltransferase (UPRT) fusion gene (FCU1 20 ) was excised from plasmid pTG 13046 (TRANSGENE SA, Strasbourg, France) as a 1189 bp fragment using XhoI and Smal, blunted with Klenow fragment and inserted into the multiple cloning site of the retroviral vector pLXIN (BD CLONTECH, Heidelberg, Germany). This retroviral construct was called pL(FCU1)IN. Restriction endonucleases and DNA modifying enzymes were from Roche Diagnostics, Mannheim, Germany.
Virus production and generation of stable-transduced bulk cultures NXS2pLXIN and NXS2pL(FCU1)IN The packaging cell line GP-293 (BD-CLONTECH) was transfected with pL(FCU1)IN and pVSV-G (BD-CLON-TECH) or with pLXIN and pVSV-G as a control using the liposomal transfection reagent GenePORTER (Gene Therapy Systems Inc., Erlangen, Germany) according to the manufacturer's instructions. Viral supernatants from transiently transfected GP-293 cells diluted 1:5 with serum-free DMEM medium were used to transduce NXS2 cells according to the manufacturer's manual. Stable bulk cultures of NXS2pLXIN and NXS2pL(FCU1)IN were generated using neomycin at a concentration of 0.7 mg per ml for 14 days. 
MTT assay
MTT assay was performed as described previously. In vitro bystander effect assay NXS2pL(FCU1)IN were mixed with NXS2 resulting in increasing ratios of NXS2pL(FCU1)IN. Mixed cells (1.5 Â 10 3 ) were seeded in collagen-coated 96-well-plates, incubated overnight and exposed to 1 mM 5-FC for 5 days. Viability was measured by MTT assay.
In vitro enrichment-eradication
Mixtures of NXS2pL(FCU1)IN and NXS2 containing 0.8 and 1.6% NXS2pL(FCU1)IN were enriched with 12.5 mM PALA and 5 mM cytosine for 7 days or were left untreated. On day 7, cells were trypsinized and, to prevent overgrowth, replated at a density of 1.5 Â 10 3 in collagencoated 96-well-plates and exposed to 1 mM 5-FC for 5 days. Viability was measured by MTT assay.
Determination of cytosine in plasma
Mouse plasma samples were purified by serial extraction on diatomaceous earth and graphitized carbon black columns. 22 The purified samples were analyzed by reversed phase gradient high-pressure liquid chromatography on a Reprosil-Pur C18 AQA column at 221C with a flow rate of 0.3 ml/min. Mobile phase A: 10 mM phosphate buffer, pH 7.0. Mobile phase B: methanol/ water/acetic acid 80:20:0.1, (v/v/v). Gradient: 100% A for 3 min; linear gradient to 60% A over 2 min; isocratic at 60% A for 5 min; linear gradient to 100% A over 4 min. For detection and quantification of cytosine the threedimensional data fields were recorded with a photodiode array detector at 215 and 269 nm. The method was fully validated and yielded an overall detection limit of cytosine of 0.3 ng/ml plasma.
Cytosine pharmacokinetics
Six-to 8-week-old female A/J mice (Harlan Winkelmann, Borchen, Germany) were injected i.p. with 500 m1 of 70 mM cytosine dissolved either in water or a g-cyclodextrin derivative dissolved in a 1% lactic acid solution that yielded a cytosine g-cyclodextrin complex stock solution containing 173 mM cytosine. At indicated time points, blood was collected by cardiac puncture, plasma was separated by centrifugation, stored on dry ice and kept at À801C until analysis.
In vivo enrichment
Six percent NXS2pL(FCU1)IN labeled with DiI were mixed with 94% unlabeled NXS2 cells. 2 Â 10 6 cells of this mixture were injected subcutaneously into six-to 8-weekold female A/J mice. Three days later, when tumors were palpable, mice were randomly distributed into two groups. The enrichment group (n ¼ 5) received three doses of 5 mg PALA in 200 ml 0.9% sodium chloride i.p. (days 3, 6 and 10) and a daily i.p. injection of 86.5 mmol cytosine g-dextrin complexes in 500 ml of 1.0% lactate buffer. To further increase cytosine delivery, cytosine was also added to the drinking water of this group at a concentration of l g/130 ml. The control group (n ¼ 5) received daily i.p. injections of 500 ml 1.0% lactate buffer only. When tumors had reached an average volume of 200 mm 3 (around day 12), animals were killed, tumors were procured, cryopreserved, cryosectioned (CM 1850, Leica Microsystems, Nussloch, Germany) and assessed using a fluorescent microscope (AX 70, Olympus, Stuttgart, Germany). Pictures were taken with a CC-12 camera and digitally processed (Soft Imaging System, Muenster, Germany).
In vivo enrichment and eradication Six-to 8-week-old female A/J mice were injected subcutaneously with 2 Â 10 6 cells containing 6% NXS2pL(FCU1)IN and 94% NXS2. Three days later, when tumors were palpable, treatment was started. Control mice received daily injections of 500 m1 1% lactate buffer from day 3 to 12. Cytosine was given orally at a concentration of 1 g per 130 ml in the drinking water and additionally as daily i.p. injections of 500 m1 cytosine g-cyclodextrin solution. PALA was administered as intraperitoneal injection of 5 mg in 200 m1 0.9% sodium chloride solution. 5-FC was given systemically daily as intraperitoneal injection of 12.5 mg in 600 m1 PBS. Tumor size was measured every second day and tumor volume calculated as volume ¼ longest diameter Â (shortest diameter) 2 Â 0.4. Experiments were terminated when tumors started to bleed because of excessive size.
Results
Response of NXS2 and its derivatives to 5-FC, PALA and cytosine We first determined the response of NXS2 and its derivatives to 5-FC, PALA and cytosine. The prodrug 5-FC killed NXS2pL(FCU1)IN depending on dose while sparing mock-transduced NXS2pLXIN and wild-type NXS2 (Figure 2a) . Thus, 5-FC-induced cell death was selective with a broad therapeutic range. Incubation of NXS2pL(FCU1)IN, NXS2pLXIN and NXS2 with increasing concentrations of the competitive enzyme inhibitor PALA for 7 consecutive days demonstrated an equal degree of cytotoxicity in all three cell derivatives as measured by MTT assay (Figure 2b ). This indicates that the sensitivity to this specific pyrimidine de novo synthesis inhibitor is not altered by the FCU1 gene product or by the transduction and selection process. When NXS2 and its derivatives were exposed to increasing concentrations of the pyrimidine base cytosine for 7 consecutive days, no toxicity was observed (Figure 2c ). This shows that cytosine can be used in the proposed enrichment strategy without exerting untoward effects of its own.
Cytosine attenuates PALA-induced cytotoxicity selectively in FCU1 expressing cells To determine, whether FCU1 expressing cells can be selectively rescued from PALA-induced cytotoxicity by sole addition of cytosine, NXS2pL(FCU1)IN, NXS2pLXIN and NXS2 were exposed to 12.5 mM PALA in the presence of increasing concentrations of cytosine. This concentration of PALA was chosen because it kills a large percentage (about 80%) of all three cell lines in vitro, if no cytosine is added (see Figure 2b) . Indeed, we observed a dose-dependent protective effect of cytosine against PALA in NXS2pL(FCU1)IN (Figure 3a) . When the cytosine concentration reached 10 mM, 80% of NXS2pL(FCU1)IN cells were protected from the cytotoxic effects of PALA. In contrast, sensitivity of NXS2pLXIN and wild-type NXS2 to PALA was not altered by cytosine even at high concentrations. These data show that cytosine selectively and efficiently attenuates PALA-induced cytotoxicity in NXSpL(FCU1)IN cells, without the need of inosine supplementation.
PALA and cytosine effectively enrich FCU1 expressing cells Success of the enrichment-eradication strategy hinges on its ability to enrich a small initial share of FCU1 cells to a final share sufficiently high for a subsequent complete bystander effect. To determine the post-enrichment shares as a function of the pre-enrichment shares, we performed a cocultivation experiment by mixing Dil-labeled NXS2pL(FCU1)IN with unlabeled NXS2 and exposing the mixture to 12.5 mM PALA and 5 mM cytosine for 7 days. These concentrations of PALA and cytosine were chosen because they allow substantial numbers of NXS2pL(FCU1)IN cells to survive, without having to resort to excessively high concentrations of cytosine (see Figure 3a) . occurred in the PBS-treated controls (Figure 3b ). Enrichment was not caused by differences in proliferation, as no relevant differences in doubling time were observed (data not shown). Taken together, the strategy allows for an efficient enrichment of the suicide gene-bearing cells from a low share up to a level, at which a complete bystander effect can be expected.
Efficient enrichment of low shares of NXS2pL(FCU1)IN allows for a near-complete bystander effect in vitro
Next we investigated, whether a very small share of cells carrying FCU1 can be enriched sufficiently to subsequently allow for a complete bystander effect following administration of 5-FC. As a complete bystander effect required around 10% of NXS2pL(FCU1)IN (Figure 4a ) and because a pre-enrichment share of between 0.8 and 1.6% sufficed to reach this threshold by enrichment (Figure 3b ), pre-enrichment ratios of 0.8 and 1.6% were chosen for an in vitro enrichment-eradication experiment. 
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High and prolonged cytosine plasma levels can be achieved in vivo To show, that the high cytosine concentrations required for effective rescue in vitro can also be achieved in vivo, we conducted pharmacokinetic studies in female A/J mice.
Complexed with a g-cyclodextrin derivative, a carbohydrate molecule that improves the solubility of cytosine and slows down its excretion, cytosine reached peak plasma levels of 2 mM and exhibited a half-life of 100 min after i.p. bolus injection ( Figure 5 ). No toxicity was noted during the observation period nor were gross signs of toxicity observed during autopsy. Thus, cytosine in gcyclodextrin administered systemically is suitable for in vivo enrichment.
NXS2pL(FCU1)IN can be enriched in vivo
As enrichment may be less efficacious in vivo than in vitro, we reasoned that a higher pre-enrichment share of NXS2pL(FCU1)IN is needed in vivo to allow for enrichment up to the threshold required for an effective bystander effect. We therefore chose a pre-enrichment share of 6% Dil-labeled NXS2pL(FCU1)IN mixed with NXS2 to be injected s.c. into mice. Palpable tumors were treated with PALA and cytosine administered systemically for 7 days. This led to clear enrichment of NXS2pL(FCU1)IN, however, enrichment was focal. Areas of marked enrichment (Figure 6a , right panels) were surrounded by areas devoid of NXS2pL(FCU1)IN. Without enrichment, the share of NXS2pL(FCU1)IN did not increase from its initial level (Figure 6a , left panels). These data show that enrichment is feasible in vivo despite the complexity added by the pharmacokinetics of cytosine and PALA. Weight loss during enrichment did not exceed 15% of body weight, no mice died during enrichment and no gross signs of toxicity were noted during autopsy, ruling out severe adverse effects of enrichment.
The enrichment-eradication strategy decreases tumor growth Finally we investigated, whether the enrichment-eradication strategy functions in vivo. To prove the principle, we opted to transfer FCU1 ex vivo to avoid variability of gene transfer efficacy and transgene expression. Based on Plasma level of cytosine (mM) Figure 5 Increased and prolonged plasma levels of cytosine when complexed with g-cyclodextrin. Six-to 8-week-old female A/J mice were injected i.p. with 70 mM cytosine dissolved in 500 ml water or complexed with g-cyclodextrin in 500 ml lactic acid solution. Following injection mice were killed at the time points indicated and 0.5-1.0 ml blood was aspirated by cardiac puncture. For each time point the plasma of two mice was pooled and cytosine levels were determined by high-pressure liquid chromatography. preliminary experiments, 10 days were chosen for both the enrichment and the eradication period of this strategy. As a control, the sequence of enrichment followed by eradication was inverted ('inverse therapy': 5-FC followed by PALA and cytosine). This required an additional control group 'early eradication' (5-FC followed by a period without drugs). 'Late eradication' (an initial period without drugs followed by 5-FC) served as a further control. We observed a clear trend towards slowing tumor growth in the mice receiving enrichment-eradication therapy (Figure 6b ). Tumor growth was slower compared to 'late' (and 'early') 'eradication' and also compared to 'inverse therapy'. The latter rules out a mere additive effect of the enrichment and eradication blocks. Interestingly, PALA alone was ineffective and did not add to the effect of 5-FC during 'inverse therapy'. As expected, cytosine alone did not influence tumor growth.
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Taken together, these data show that enrichment of a low percentage of FCU1-bearing cells followed by eradication decreases tumor growth in vivo.
Discussion
Poor gene transfer efficiency hampers cancer gene therapies relying on in vivo gene transfer into tumor cells. We provide first time proof of principle that compensation of poor gene transfer is possible by in vivo enrichment of transduced tumor cells, allowing subsequently for increased tumor control.
CD appeared especially well suited for an enrichmenteradication approach as its gap junction-independent negative selection function is well established and because it acts upon the pyrimidine metabolism, which is amenable to manipulations leading to positive selection. Positive selection has been shown to depend on the addition of inosine to metabolize sufficient uridine necessary for rescue. We modified the CD/5-FC plus PALA system by utilizing UPRT, expressed from a CD-UPRT fusion gene, 20 thus obviating the need for inosine. Simplified in this way, the system could be used for positive selection in vivo, the first time a suicide gene has been employed for this purpose. Although cancers overexpressing uracil phosphoribosyl transferase would potentially limit this approach, we are not aware of such cancers.
The enrichment-eradication approach is counterintuitive as enriching tumor cells may appear to be counterproductive for eradication of the tumor. However, the strong bystander effect that can be achieved after enrichment outweighs the initial decrease in tumor cell kill, thus resulting in a net increase of tumor cell kill.
FCU1-mediated enrichment-eradication successfully decreased tumor growth. However, no cures were achieved. Several factors may account for this. First, enrichment was limited, suggesting that, in vivo, resistance of NXS2pL(FCU1)IN and/or response of NXS2 to PALA were not sufficient. Plasma levels of PALA may have been to low, possibly explaining the lack of severe toxicity. Thus, increasing the dose of PALA may enhance tumor control, however, increased toxicity might ensue. Also, plasma levels of PALA may not have been sustained enough. Thus, continuous infusion of PALA may be more efficacious. Furthermore, it has been shown in patients that PALA diminishes blood flow through tumor vessels, 23 which would decrease further delivery of PALA to the tumor. Thus, tumors initially sensitive to PALA may become resistant with increasing duration of PALA administration. Therefore, although enrichment would occur during the enrichment period, tumor growth would not decrease with prolonged PALA therapy. This may have accounted for the lack of tumor control when PALA was given as a single drug. Second, cytosine plasma levels may have been insufficient as bolus infusion led to only short periods of time with cytosine plasma levels above the threshold necessary for enrichment. Thus, continuous infusion of cytosine may be more efficacious for enrichment. Third, NXS 2pL(FCU1)IN formed clusters while being enriched, most likely because resistant FCU1 cells grew clonally. Cluster formation will localize the bystander effect and thus impede it. Fourth, in contrast to the slowly growing tumors in humans, the rapidly growing murine tumors pose problems of time constraints for both the enrichment and the eradication phase.
Final proof of the feasibility of the enrichmenteradication strategy will rest on showing its efficacy following in vivo transfer of FCU1. Transducing cancer cells ex vivo and mixing transduced with non-transduced cells before implantation creates an artificial system causing a wider distribution of FCU1-carrying cells than would occur by vector-mediated delivery of FCU1 to a pre-formed tumor. Mixing cells very likely leads to better cell killing when the prodrug is given. As we have shown in Figure 6a , growth of the selected cells occurs in a focal manner. Thus, achieving a broad initial distribution of the FCU1 gene, such as by employing replicating vectors or convection-enhanced gene transfer, will be critical to effective application of this strategy.
To improve enrichment-eradication based on CD, several approaches can be envisioned. PALA may be substituted by other inhibitors of pyrimidine de novo synthesis, which might be more efficient in controlling growth of bystander cells in vivo. Although the high plasma level of cytosine needed for rescue did not lead to marked adverse effects in the mice, its effect in humans is unknown. In addition, the need for cytosine adds complexity to CD-mediated enrichment-eradication. Other genes may be found to be more efficient than UPRT in bypassing rate-limiting steps of the pyrimidine salvage pathway, ideally obviating the need for exogenous cytosine.
Beyond the CD system, clinical applicability and efficacy of enrichment-eradication cancer gene therapy may be improved by designing genes for this purpose, such as fusing a cancer drug resistance gene with a suicide gene.
Enrichment-eradication shares its aim of increasing the bystander effect with several other cancer gene therapy approaches. Replicating oncolytic viruses promise to overcome low initial infection rates of tumor cells by subsequent spread to bystander cells (reviewed by Thorne et al. 24 and Mathis et al.
25
) Tumor vaccination, cell mediated gene therapy and antiangiogenic tumor therapies also rely on a bystander effect. An attractive feature of enriching cells in vivo using a suicide gene is the fail-safe mechanism of this approach. Increased resistance against the positively selecting drug is invariably linked with increased susceptibility to the negatively selecting drug, both being mediated by the same gene. If silencing of the suicide gene should occur in vivo, it would affect both functions. Also, because the same gene mediates both resistance and susceptibility, the risk of conferring only resistance to tumor cells by in vivo recombination is nil. Given its safety, this strategy may be employed for the enrichment of hematopoietic stem or progenitor cells, with the possibility of complete eradication, if untoward effects like transformation should occur. It may also be used to titrate a beneficial state of mixed chimerism of genetically modified and endogenous stem or progenitor cells. Similarly, applications in adoptive transfer of lymphocytes can be envisioned. However, in these scenarios and in contrast to enrichment-eradication in tumor cells, the potential immunogenicity of the fusion gene may be detrimental.
In conclusion then, enrichment-eradication is a principle with the potential to compensate the consequences of low in vivo gene transfer efficacy, a major hurdle for effective cancer gene therapy.
